ACD Labs Logo
MENU

Is the Pharma Industry Developing Cultural Intelligence?

Published online at Pharma's Almanac.

by Cynthia Challener

Andrew Anderson (Vice President of Innovation and Informatics Strategy, ACD/Labs) responds to how technology will impact pharma in Pharma Almanac's Q1 2020 issue.

The effort required to get a drug approved for the market today is far more than that from 30 years ago, yet the recent string of impurity-related drug recalls from the FDA has increased the pressure to effectively and comprehensively manage the drug substance and drug product data life cycle before pharmaceuticals are circulated to patients.

At a time when the amount of data that organizations are collecting is more disparate and greater in volume than ever before, being able to share data effectively and demonstrate data integrity are additional drivers for better data management. Dealing with complex data sets continues to be a major concern for researchers and pharmaceutical executives, so digitization efforts that help streamline workflows and help address this data management challenge will lead to an evolution in the technology stacks of pharmaceutical R&D. Effective, integrated data management technologies will accelerate organizations' decision-making processes and maximize productivity by efficiently, and correctly, interpreting the data without the need for human intervention for every decision.

Integration of machine learning—and AI in general—is likely to grow over the next decade, by matching the power of human intelligence with intelligent technology. Machine learning will assist scientists in experimental design, relying on historical data from successful and unsuccessful experiments to provide guidance. This, too, will empower scientists to be more efficient in the laboratory, accelerating R&D in the pharmaceutical industry

View the complete article online at Pharma's Almanac